NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 157)
Posted On: 07/18/2019 2:48:44 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Consistently Outperforms Industry Standards
Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently reported that clinical lab tests conducted with live animals demonstrated that its new, enhanced version of DehydraTECH(TM) can deliver eight times more CBD into the blood and 19 times more CBD into the brain tissue than standard industry formulations (http://nnw.fm/91ZQd). An article discussing the company reads, “LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees. . . . In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137% more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://nnw.fm/SU1sL). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently reported that clinical lab tests conducted with live animals demonstrated that its new, enhanced version of DehydraTECH(TM) can deliver eight times more CBD into the blood and 19 times more CBD into the brain tissue than standard industry formulations (http://nnw.fm/91ZQd). An article discussing the company reads, “LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees. . . . In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137% more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://nnw.fm/SU1sL). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼